Researchers reported that genome-wide methylome profiling of circulating cell-free DNA can predict outcomes in castration-resistant prostate cancer. The study described a new approach designed to forecast patient trajectories by reading epigenetic signatures in plasma-derived DNA. The report frames the work as a prognostic step for CRPC, where clinicians currently rely on a mix of clinical factors, imaging and serum markers that can be imprecise for anticipating downstream response or survival. If validated in larger cohorts, methylome-based liquid biopsy profiling could expand precision oncology tools beyond mutation detection to include epigenetic state information, potentially informing risk stratification and follow-up treatment selection.